Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are indicated in type 2 diabetes and obesity for their high efficacy in controlling glycaemia and inducing body weight loss, respectively. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.